End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.29 USD | -0.60% | -4.11% | +15.77% |
30/04 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
30/04 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.77% | 373.22Cr | |
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+43.45% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |
- Stock Market
- Equities
- ALVO Stock
- News Alvotech
- Alvotech Says its AVT03 Study Meets Primary Endpoints as a Biosimilar to Prolia and Xgeva for Bone Health